There is a new cold chain company in town.

Dawsongroup tcs USA has officially launched in the United States, and in the process, is introducing its modular cold chain system—known as the Superbox—to the American market.¹

The new South Carolina-based company is financially supported by Dawsongroup tcs, a temperature-controlled solutions powerhouse in its own right, with more than 30 years of experience in Europe and a lineup of over 30,000 assets. According to the company, standard logistics in the US are often hindered by needing to account for 12-18-month construction timelines for permanent cold storage setups. Dawsongroup tcs USA, on the other hand, reportedly offers “adaptable, precision environments” that can be implemented in only weeks.

What makes the Superbox different from traditional cold storage solutions?

The Superbox is a versatile, modular, and temperature-controlled infrastructure designed to address the critical need for speed and compliance across a wide spectrum of US industries. In the pharmaceutical sector, where cold chain failures can result in $20 billion to $35 billion in annual product losses, the system provides the ultra-precise control and backup protection necessary to protect sensitive biologics and vaccines.

How does the Superbox support pharmaceutical compliance and risk reduction?

“The US market has been operating under the same rigid cold chain model for decades, and it is long overdue for more modern solutions,” said Aidan McCauley, president of Dawsongroup tcs USA. “Whether a business is managing a million-dollar pharmaceutical shipment, sensitive chemical compounds, or high-volume food distribution, the risk of infrastructure failure is the same. The Superbox isn't just an upgrade: it’s a fundamental rethinking of the cold chain that allows companies across all sectors to eliminate risk and scale with total confidence.”

What are the financial and operational benefits of a modular cold chain model?

From a financial perspective, the product itself can also be leased, removing any fixed investment from the equation. In turn, pharma manufacturers can then gauge their processes on a real-time basis, as opposed to running the risk of additional assets being underused.

The Superbox is 50% wider than a standard refrigerated container and is designed to meet FDA’s regulatory standards, including FDA and good manufacturing practice requirements. It also has automated temperature controls, as well as real-time and temperature monitoring.

What other innovations are emerging in pharma cold chain and packaging?

In other pharma cold chain news, TemperPack, who specializes in sustainable thermal packaging, recently relocated its Green Cell Foam production plant from Holt, MI to a larger 135,000 square-foot facility in Lansing. The new site not only welcomes expansion, but features a boost in equipment and an increase in operational efficiency.

Specifically, the move represents a 60% boost in manufacturing space, which allows the company to further tackle demand for its branded insulation products.

Essentially, TemperPack's goal is to offer environmentally friendly alternatives to one’s traditional packaging materials. In this case, Green Cell Foam is a plant-based, certified compostable insulation material that reduces environmental impact and offers performance that’s compareable to polystyrene foam, often known as EPS.

Reference

1. Dawsongroup tcs USA Introduces Modern Temperature-Controlled Solutions in the U.S., Challenging Outdated Supply Chain Infrastructure. GlobeNewswire. January 14, 2026. Accessed January 16, 2026. https://www.globenewswire.com/news-release/2026/01/14/3218721/0/en/Dawsongroup-tcs-USA-Introduces-Modern-Temperature-Controlled-Solutions-in-the-U-S-Challenging-Outdated-Supply-Chain-Infrastructure.html